Genomics in Cancer Care Market Revenue to Attain USD 108.69 Bn by 2035

Published: 16 Feb 2026

Author: Precedence Research

Share:

Genomics in Cancer Care Market Revenue and Trends 2026 to 2035

The global genomics in cancer care market revenue was valued at USD 24.39 billion in 2025 and is expected to attain around USD 108.69 billion by 2035, growing at a CAGR of 28.32% during forecast period.The growth of the market is driven by several factors, including the growing demand for genomics-based tools for early detection and screening and the rapid expansion of next-generation sequencing (NGS) technologies.

What are the Major Factors Driving the Growth of the Genomics in Cancer Care Market?

The increasing incidence of cancer and growing emphasis on personalized medicine are the major drivers, accelerating the growth of the market. Cancer is one of the leading causes of death globally, which has led to an increasing demand for precise genomic diagnostics for early and accurate diagnosis. Genomics enables customized treatment plans that increase the need for targeted therapies. The growth of the market is also primarily supported by the rising demand for precision oncology and the increasing integration of AI and bioinformatics.

Segment Insights

• By technology, the next-generation sequencing (NGS) segment contributed the biggest market share of approximately 48% in the market in 2025. The growth of the segment is driven by its ability to provide low-cost, high-throughput, and rapid genomic profiling. This enables precision medicine through early cancer detection, targeted therapy selection, and liquid biopsies. In addition, the rise of liquid biopsy for non-invasive tumor profiling and monitoring cancer recurrence drives the usage of next-generation sequencing (NGS).
• By application, the cancer diagnosis & early detection segment held the dominant position with a share of approximately 32% in 2025, owing to the rising prevalence of cancer, the rising need for proactive screening solutions, and rapid technological advancements in Next-Generation Sequencing (NGS) & liquid biopsy. Additionally, the rise in government funding for initiatives to increase insurance coverage for genetic tests is significantly accelerating the adoption of early detection methods. 
• By end-user, the hospitals & cancer centers segment held the largest market share in the genomics in cancer care market with approximately 42% in 2025. Hospitals & cancer centers are the major end users in the genomics in cancer care market. Hospitals & cancer centers are equipped with advanced diagnostic services and rapid technological advancements such as Next-Generation Sequencing (NGS) and liquid biopsy technologies. Hospitals & cancer centers have skilled professionals to handle sophisticated genomic testing and molecular diagnostics.
• By cancer type, the breast cancer segment held the dominant market share of approximately 26% in 2025, owing to the rising cases of breast cancer. Breast cancer is the most commonly diagnosed cancer among women globally, leading to the increasing demand for early detection. Genomic testing in breast cancer care analyzes tumor RNA and DNA to guide personalized treatment, particularly in assessing the need for chemotherapy in early-stage hormone-positive cases and identifying targeted therapy options for advanced stages.According to a new analysis by the International Agency for Research on Cancer published in February 2025, Global breast cancer incidence is projected to rise by 38% and related deaths by 68% by 2050. The paper analysed the global burden of female breast cancer overall and by age group in 185 countries using the WHO database GLOBOCAN, and 10-year trends in incidence in 50 countries and mortality rates in 46 countries using the cancer incidence in five continents and the WHO mortality databases.

Regional Insights

North America holds the dominant share in the global genomics in cancer care market. The region has a well-established healthcare system and widespread adoption of advanced technologies.

The region’s leadership is driven by the increasing emphasis on personalized medicine, the increasing burden of cancer, growing demand for liquid biopsy and non-invasive diagnostics, and favorable regulatory frameworks (FDA) and reimbursement policies for genomic tests. Moreover, the increasing adoption of next-generation sequencing (NGS) in clinical diagnostics is propelling the growth of the market in the region.

On the other hand, Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period. The fastest growth of the region is attributed to the rising investments in diagnostic infrastructure, increasing need for non-invasive diagnostic tools, increasing emphasis on screening programs and early detection, high cancer incidence rates, and the rising government initiatives to increase the screening and diagnostic rates. In addition, the increasing patient population with cancer, along with the rising number of hospitals, cancer centers, and diagnostic laboratories, is expected to boost the market’s growth in the Asia Pacific region.

Genomics in Cancer Care Market Coverage

Recent Developments

• In January 2026, SOPHiA GENETICS, a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret, and translate diagnostic results into clinical practice. As part of the collaboration, MD Anderson and SOPHiA GENETICS are launching a series of research and development programs and co-developing an advanced next-generation sequencing oncology test.(Source: https://www.prnewswire.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7696

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344